Wooree Bio우리바이오
082850 · KOSDAQ · ₩082850 · 우리바이오
₩4,260▲ ₩70 (1.67%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩1T | ₩1.2T | ₩1.3T | ₩1.4T | ₩1.5T |
| Cost of sales | ₩949B | ₩1.1T | ₩1.1T | ₩1.2T | ₩1.4T |
| Gross profit | ₩95B | ₩119B | ₩116B | ₩115B | ₩116B |
| Operating income | ₩952M | ₩15B | ₩26B | ₩34B | ₩43B |
| Net income | −₩10B | ₩8.2B | ₩19B | ₩25B | ₩44B |
| Net income to shareholders | −₩9.4B | ₩4.7B | ₩16B | ₩22B | ₩33B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩762B | ₩610B | ₩586B | ₩559B | ₩664B |
| Current assets | ₩569B | ₩405B | ₩453B | ₩413B | ₩499B |
| Cash and equivalents | ₩107B | ₩69B | ₩60B | ₩66B | ₩86B |
| Total liabilities | ₩501B | ₩341B | ₩334B | ₩332B | ₩465B |
| Current liabilities | ₩451B | ₩281B | ₩317B | ₩304B | ₩425B |
| Borrowings | ₩117B | ₩104B | ₩64B | ₩84B | ₩96B |
| Total equity | ₩261B | ₩269B | ₩251B | ₩227B | ₩199B |
| Shareholders' equity | ₩205B | ₩212B | ₩199B | ₩179B | ₩155B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩35B | ₩36B | ₩27B | ₩43B | ₩50B |
| Capital spending | ₩22B | ₩82B | ₩10B | ₩13B | ₩12B |
| Free cash flow | ₩13B | −₩46B | ₩16B | ₩30B | ₩39B |
Consolidated where available. Amounts in won.
Also known as: Wooree Bio / 우리바이오 / 082850 / KRX:082850
Source: KRX statistical information